Aller au contenu principal
xMedica

NCT06956014ClinicalTrials.gov

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not…

Phase 3810 participants recherchés43 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-05-02; recorded start 2026-09-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Vertanical GmbH)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 810 participants (target), run at 43 sites.

How this score is built
  • Enrolment29/40

    810 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale1/10

    Vertanical GmbH has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Affections

  • Lumbosacral Radiculopathy

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Participants ≥ 18 years of age, all sexes * Participant voluntarily provided written informed consent * Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation Exclusion Criteria: * Pregnant or breastfeeding female patients * Known history of previous or current severe psychiatric disorder as per DSM-5 (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication * Cardiovascular event or clinically significant cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long QT syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement810 participants recherchés

Promoteur et collaborateurs

  • Vertanical GmbH Promoteur

Groupes et interventions

  • VER-01 Dose 1EXPERIMENTAL
  • VER-01 Dose 2EXPERIMENTAL
  • PlaceboPLACEBO_COMPARATOR

Interventions

  • Autre Placebo

    Comparator without active ingredient

  • Médicament VER-01

    Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

Critères de jugement

  1. Critère de jugement principal

    Efficacy based on pain reduction

    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

    Délai From Baseline to Treatment Week 12

Dates

Dates
Date de début22 septembre 2026 (réelle)
Achèvement principal1 septembre 2028 (estimée)
Achèvement1 septembre 2028 (estimée)
Première publication2 mai 2025 (réelle)
Dernière mise à jour19 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

43 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Central Texas Clinical Research, LLCAustinTexasEn recrutement
Boston Clinical TrialsBostonMassachusettsEn recrutement
Bradenton Research CenterBradentonFloridaEn recrutement
DFW Clinical TrialsCarrolltonTexasEn recrutement
Epic Medical Research - CarroltonCarrolltonTexasEn recrutement
Clinitiative - Clinical Trials of South Carolina - CharlestonCharlestonSouth CarolinaEn recrutement
Epic Medical Research - ChickashaChickashaOklahomaEn recrutement
Velocity Clinical Research - ClevelandClevelandOhioEn recrutement
Epic Medical Research - DeSotoDeSotoTexasEn recrutement
Mountain View Clinical ResearchDenverColoradoEn recrutement
Innovare Research Group IFriendswoodTexasEn recrutement
AGA Clinical TrialsHialeahFloridaEn recrutement
HD Research - Memorial Hermann VillageHoustonTexasEn recrutement
Perfizien Clinical Research LLCHoustonTexasEn recrutement
Synergy Groups Medical - Southeast HoustonHoustonTexasEn recrutement
Green Leaf Clinical TrialsJacksonvilleFloridaEn recrutement
R & H Clinical ResearchKatyTexasEn recrutement
Alliance for Multispecialty Research - KnoxvilleKnoxvilleTennesseeEn recrutement
Epic Clinical Research - LewisvilleLewisvilleTexasEn recrutement
Central Medical Research InstituteLong BeachCaliforniaEn recrutement
Tekton Research - LongmontLongmontColoradoEn recrutement
K2 Medical Research - Maitland IIMaitlandFloridaEn recrutement
Velocity Clinical Research - MedfordMedfordOregonEn recrutement
Alma Clinical ResearchMiamiFloridaEn recrutement
Floridian Research Institute LLC IMiamiFloridaEn recrutement
AMR MobileMobileAlabamaEn recrutement
Monroe Biomedical Research - MonroeMonroeNorth CarolinaEn recrutement
Alliance for Multispecialty Research - NorfolkNorfolkVirginiaEn recrutement
Conquest Research - Lake NonaOrlandoFloridaEn recrutement
Alfa Medical Research - Pembroke PinesPembroke PinesFloridaEn recrutement
Flourish Research - PhiladelphiaPlymouth MeetingPennsylvaniaEn recrutement
United Medical ResearchPort OrangeFloridaEn recrutement
Boeson ResearchProvoUtahEn recrutement
CenExel JBR - Salt Lake CitySalt Lake CityUtahEn recrutement
Elixia Clinical Research CollaborativeSpringfieldMassachusettsEn recrutement
Professional Health Care of PinellasSt. PetersburgFloridaEn recrutement
Velocity Clinical Research - SuffolkSuffolkVirginiaEn recrutement
Alliance for Multispecialty Research - Tempe ITempeArizonaEn recrutement
Alliance for Multispecialty Research - Wichita EastWichitaKansasEn recrutement
Grayline Research CenterWichita FallsTexasEn recrutement
Progressive Medicine of the Triad, LLCWinston-SalemNorth CarolinaEn recrutement
Conquest Research - Winter ParkWinter ParkFloridaEn recrutement
Vitalix ClinicalWorcesterMassachusettsEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 19 novembre 2026

    Site ajouté

    11 sites added (43 total)

    3243

  2. 2 novembre 2026

    Site ajouté

    9 sites added (32 total)

    2332

  3. 21 octobre 2026

    Site ajouté

    1 site added (23 total)

    2223

  4. 19 octobre 2026

    Site ajouté

    21 sites added (22 total)

    122

  5. 28 septembre 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  6. 28 septembre 2026

    Site ajouté

    1 site added (1 total)

    01

  7. 28 septembre 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING